Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
Objectives for this study are two-fold:
1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated
phase CML in relation to response rate, duration of response, and survival.
2. To assess the toxicity of SCH66366 in these patients.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Jorge Cortes, MD
UT MD Anderson Cancer Center
United States: Food and Drug Administration
|MDAnderson Cancer Center||Houston, Texas 77030|